Fig. 4. MPC is a regulator of luminal lineage identity in prostate cancer.

a, Western blot analysis of luminal markers KRT8 and KRT18 in SKO and DKO mouse prostate organoids treated with vehicle or 10 μM UK5099 for 5 d. b, Heatmap of canonical basal and luminal markers from RNA-seq of vehicle- and 10 μM UK5099-treated DKO organoids. c,d, Correlation analysis of luminal signature score and MPC1 (c) or MPC2 (d) z-scores in treatment-naive prostate cancer samples from the SMMU dataset²⁹. e,f, Correlation analysis of luminal signature score and MPC1 (e) or MPC2 (f) z-scores in metastatic castration-resistant prostate cancer samples from the Beltran et al. dataset³⁰. g,h, RNA abundance of MPC1 (g) or MPC2 (h) in adenocarcinoma (adeno) or neuroendocrine prostate cancer (NEPC) samples from the Beltran et al. dataset³⁰. i,j, RNA abundance of MPC1 (i) or MPC2 (j) in adeno or NEPC samples from the Nguyen et al. PDX dataset³¹. Correlation analysis was performed using Spearman’s correlation with a two-tailed P value. For all panels, error bars represent s.e.m. P values in g–j were calculated using an unpaired two-tailed t-test with Welch’s correction. mCRPC, metastatic castration-resistant prostate cancer.

Source data